A highly popular group of weight loss and diabetes drugs is still hard to find in the U.S.
The dominant manufacturers of those treatments, Eli Lilly and Novo Nordisk , are making progress toward changing that.
Patients using current autoinjectors for weight loss and diabetes drugs go through four different pens per month.
Eli Lilly expects supply for Zepbound, Mounjaro and other incretin drugs to remain "quite tight" in the near- to mid-term as demand remains high, Ashkenazi said.
On the day Eli Lilly reported earnings, shares of the company jumped more than 5% on the raised guidance and supply updates.
Persons:
Eli Lilly, Anat Ashkenazi, There's, Ashkenazi, David Ricks, —, Lilly, Chris Schott
Organizations:
U.S, Novo Nordisk, Nexus Pharmaceuticals, JPMorgan
Locations:
North Carolina, Indiana, Ireland, Germany, Europe, U.S